FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer - Reuters PDF Print
ReutersVOTRIENT will join existing targeted therapies to provide physicians with a new oral treatment option to their patients with advanced renal cell cancer.

... read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.